CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its expertise in the areas of in-vitro diagnostics (IVDs) and medical […]
CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its in vitro diagnostics (IVDs) and medical device expertise, announced today that one of its clinical research study clients, Nuclein, LLC, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for the DASH® SARS-CoV-2 & Flu A/B Test for use on the DASH® Rapid PCR System.
As we reflect on 2024, CovarsaDx has much to celebrate. This year was marked by milestones that showcased our commitment to advancing diagnostic innovation
Clinical research, especially in the fields of in-vitro diagnostics (IVD) and medical devices, plays a vital role in advancing healthcare solutions and improving public health. However, a pervasive issue facing the industry is the erosion of public trust due to misinformation and past ethical missteps such as the Tuskegee Syphilis Study.
CovarsaDx is thrilled to welcome Tania Vogel to the team as our newest leader in Regulatory and Quality Assurance. With a career spanning nearly two decades and a resume that reads like a blueprint
CovarsaDx is seeking a dedicated and detail-oriented Quality/TMF Administration Assistant to play a pivotal role in managing Trial Master Files
CovarsaDx’s Vice President of Regulatory Affairs and Quality, Marielle Lejcher, recently shared her personal health journey on Dr. Archelle Georgiou’s Speak Up for Your Health podcast.
CovarsaDx, a clinical research organization at the forefront of in vitro diagnostics (IVD) and medical device trials, has appointed Rich Masino as senior director of strategic partnerships and business development. Bringing over 30 years of experience in biotech, pharma, and medical device diagnostics, Masino will focus on driving growth and forging strategic partnerships across CovarsaDx and ZoaDx, while reporting directly to the company’s chief executive officer (CEO).
CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its expertise in the areas of in vitro diagnostics (IVDs) and medical devices, proudly announced today that a clinical research study, conducted on behalf of Healgen Scientific, LLC, through the Independent Test Assessment Program (ITAP), part of National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech, has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for the Healgen Rapid Check® COVID-19/Flu A&B Antigen Test.
CovarsaDx is proud to announce its membership in the Medical Device Innovation Consortium (MDIC). This partnership marks a significant milestone in CovarsaDx’s ongoing mission to advance innovation in healthcare technology by providing reliable clinical validation results from an elite network of experienced investigators.